Cysteine-containing peptides having antioxidant properties

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Other Related Categories

C530S300000, C530S333000, C514S002600, C514S012200

Type

Reexamination Certificate

Status

active

Patent number

10142238

Description

ABSTRACT:
The term “homology” or “homologous” means an amino acid similarity measured by the program, BLAST (Altschul et al (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25:33 89–3402), and expressed as —(% identity n
). In measuring homology between a peptide and a protein of greater size, homology is measured only in the corresponding region; that is, the protein is regarded as only having the same general length as the peptide, allowing for gaps and insertions.

REFERENCES:
patent: 4643988 (1987-02-01), Segrest et al.
patent: 5721114 (1998-02-01), Abrahamsen et al.
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5876968 (1999-03-01), Sirtori et al.
patent: 5955055 (1999-09-01), Lees et al.
patent: 6156727 (2000-12-01), Garber et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6596544 (2003-07-01), Fogelman et al.
patent: 6617156 (2003-09-01), Doucette-Stamm et al.
patent: 6635623 (2003-10-01), Hoogeveen et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 2005/0196754 (2005-09-01), Drmanac et al.
J Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
SIGMA. Designing Custom Peptides. http://www.sigma-genosys.com/peptide—design.asp (Accessed Dec. 16, 2004). 2 pages.
HJC Berendsen. A Glimpse of the Holy Grail? Science (1998) 282. 642-643.
D Voet and JG Voet. Biochemistry, 2nd Edition.(1995). 235-241.
KH Weisgraber, et al. Apolipoprotein A-IMilano. J Biol Chem (1983) 285(1). 2508-2513.
G Utermann, et al. Eur. J. Biochem. (1984) 144. 325-331.
NCBI GenBank Accession No. NP—44320. accessed at http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi. Accessed Feb. 10, 2005. 1 page.
NCBI GenBank Accession No. XP—043694. accessed at http://www.ncbi.nlm.nih.gov/entrez/sutils/girevhist.cgi?val=XP—043694. Accessed Feb. 10, 2005. 3 pages.
Datta, et al.; “Aromatic Residue on the Nonpolar Face of Class A Amphipathic Helical Peptides Determines Biological Activity;”The Journal of Biological Chemistry; Jun. 18, 2004; pp. 26509-26517; vol. 279; No. 24; The American Society for Biochemistry and Molecular Biology, Inc.; USA.
Jia, et al.; “Thiol-bearing Synthetic Peptides Retain the Antioxidant Activity of ApolipoproteinA-I(Milano);”Biochemical and Biophysical Research Communications; Sep. 20, 2002; pp. 206-213; vol. 297; Issue 2; Elsevier Science.
Navab, et al.; “Thematic Review Series: The Pathogenesis of Atherosclerosis; The Oxidation Hypothesis of Atherogenesis: The Role of Oxidized Phosholipids and HDL;”;Journal of Lipid Research; Apr. 1, 2004; pp. 993-1007; vol. 45; The American Society for Biochemistry and Molecular Biology, Inc.
Reddy, et al. “ATP-Binding Cassette Transporter 1 Participates in LDL Oxidation by Artery Wall Cells;”Arterioscler Thromb Vasc Biol.; Nov. 2002; pp. 1877-1883; vol. 22.
Schmitz, et al.; “ATP-Binding Cassette Transporter A1 (ABCA1) in Macrophages: A Dual Function in Inflammation and Lipid Metabolism?;”Pathobiology; 2000; pp. 236-240; vol. 67; Karger AG; Basel.
Sean Ameli et al., “Recombinant Apolipoprotein A-I Milano Reduces Intimal Thickening After Balloon Injury in Hypercholesterolemic Rabbits,” Circulation, 90, 4:1935-1941, (Oct. 13, 1994).
Gerd Assman et al., “High Density Lipoproteins, Reverse Transport of Choloesterol, and Coronary Artery Disease,” Circulation, vol. 87 (No. 4), p. III-28-34, (Apr. 13, 1993).
John K. Bielicki et al., “Apolipoprotein A-IMilano and Apolipoprotein A-iParis Exhibit an Antioxidant Activity Distinct from That of Wild-type Apolipoprotein A-I,” Biochemistry, 41:2089-2096, (Jan. 2002).
Eric Bruckert et al, “The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-IMilano,” Atherosclerosis, 128:121-128, (1997).
Robert J. Brushia et al., “Baculovirus-mediated expression and purification of human serum paraoxonase 1A,” Journal of Lipid Research, 42: 951-958, (Jun. 2001).
Guido Franceschini et al., “A-IMilano Apoprotein: Decreased High Density Lipoprotein Cholesterol Levels with Significant Lipoprotein Modifications and Without Clinical Atherosclerosis in an Italian Family,” J. Clin. Invest., 66:892-900, (Nov. 1980).
Guido Franceschini et al., “Apolipoprotein A-I Milano: Accelerated Binding and Dissociation From Lipids of a Human Apolipoprotein Variant,” J. Biol. Chem. 260, 30:16321-16325, (Dec. 1985).
David W. Garber et al., “A New Synthetic class A Amphipathic peptide analogue protects mice from diet-induced atherosclerosis,” Journal of Lipid Research, 42: 545-552, (Apr. 2001).
Kristin L. Gillotte et al., “Apolipoprotein-mediated Plasma Membrane Microsolubilization,” Journal of Biological Chemistry, vol. 272 (No. 4), p. 2021-2028, (Jan. 1999).
Armando J. Mendez et al., “Synthetic Amphipathic Helical Peptides That Mimic Apolipoprotein A-I in Cleaning Cellular Cholesterol,” J. Clin, Invest., 94:1698-1705, (Oct. 1994).
Vinod K. Mishra et al., “Studies of Synthetic Peptides of Human Apoloprotein A-I Containing Tandem Amphipathic alpha-Helixes,” Biochemistry, 37: 10313-1032, (June 25, 1998).
Michael N. Oda et al., “Cysteine Substitutions in Apolipoprotein A-I Primary Structure Modulate Paraoxonase Activity,” Biochemistry, 40:1710-1718, (Jan. 19, 2001).
Palgunachari et al., “Only the Two End Helixes of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity,” Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 2:328-338, (Feb. 13, 1996).
Oscar Perez-Mendez et al., “Metabolism of Apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI PAris,” Atherosclerosis, 148: 317-326, (2000).
Basil M. Rifkind, “High-Density Lipoprotein Cholesterol and Coronary Artery Disease:Survey of the Evidence,” The Americal Journal of Cardiology, 66: 3A-6A, ( Sep. 4, 1990).
Prediman K. Shah et al., “High-dose Recombinant Apolipoprotein A-I Milano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice,” Circulation, 103:3047-3050, (Jun. 2001).
Prediman K. Shah et al., “Effects of Recombinant Apolipoprotein A-I Milano on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice,” Circulation, 97:780-785, (Mar. 1998).
Cesare R. Sirtori et al., “Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant: The Limone sul Garda Study,” Circulation, 103:1949-1954, ( Apr. 2001).
M.G. Sorci-Thomas et al., “Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity,” J. Bio. Chem., 272:7278-7284, (Mar. 14, 1997).
M.G. Sorci-Thomas et al., “The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin-cholesterol acyltransferase activation,” J. Bio. Chem., 273:11776-11782, (May 8, 1998).
Peter W.F. Wilson, “High-Density Lipoprotein, Low-Density Lipoprotein and Coronary Artery Disease,” Am J Cardiol, 66:7A-10A, (Sep. 4, 1990).
Karl H. Weisgraber et al., “A-I Milano Apoprotein: Isolation and Characterization of Cysteine-containing Variant of the A-I Apoprotein from Human High Density Lipoproteins,” J. Clin. Invest., 66: 901-907, (Nov. 13, 1980).
Karl H. Weisgraber, “Apolipoprotein A-I Milano: Detection of Normal A-I in Affected Subjects and Evidence for a Cysteine for Arginine Substitution in the Variant A-I,” J.Biol. Chem., 258 4:2508-2513, (Feb. 1983).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Cysteine-containing peptides having antioxidant properties does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cysteine-containing peptides having antioxidant properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine-containing peptides having antioxidant properties will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3737509

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.